CNGGF (Cann Group) Common Stock : $117.90 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Cann Group Common Stock?

Cann Group's quarterly common stock declined from Dec. 2023 ($122.08 Mil) to Jun. 2024 ($121.45 Mil) and declined from Jun. 2024 ($121.45 Mil) to Dec. 2024 ($117.90 Mil).

Cann Group's annual common stock declined from Jun. 2022 ($119.06 Mil) to Jun. 2023 ($119.04 Mil) but then increased from Jun. 2023 ($119.04 Mil) to Jun. 2024 ($121.45 Mil).

Cann Group Common Stock Historical Data

The historical data trend for Cann Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cann Group Common Stock Chart

Cann Group Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Common Stock

Get a 7-Day Free Trial

67.04

114.43

119.06

119.04

121.45

Cann Group Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	Get a 7-Day Free Trial											119.83	119.04	122.08	121.45	117.90

Cann Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Cann Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cann Group Ltd (OTCPK:CNGGF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CAN:Australia

Address

262-276 Lorimer Street, Ground Floor, Port Melbourne, VIC, AUS, 3207

Website

https://www.canngrouplimited.com

Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.